【导读】癌相关成纤维细胞（CAFs）被证实会促进肺癌细胞对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）产生耐药性。然而，在肺腺癌（LUAD）中，具体哪些 CAF 亚群驱动肿瘤进展以及对 EGFR-TKIs 产生耐药性，目前仍知之甚少。

2025年欧洲肺癌大会（ELCC）期间，意大利IEO欧洲肿瘤研究所IRCCS专家Antonio ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platform ...

在当今肿瘤治疗领域，新型抗肿瘤药物中的「靶向治疗药物」与「免疫检查点抑制剂」堪称闪亮双子星。靶向治疗药物需通过基因检测明确敏感靶点，从而实现精准施治；而免疫检查点抑制剂虽尚未形成统一的生物标志物评估标准，但 PD-L1 高表达通常预示着更优的治疗反应 ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...